Replimune Group (NASDAQ:REPL) Stock Price Up 9.5% – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) shares were up 9.5% during mid-day trading on Thursday . The stock traded as high as $13.56 and last traded at $13.26. Approximately 518,051 shares traded hands during trading, a decline of 50% from the average daily volume of 1,040,285 shares. The stock had previously closed at $12.11.

Analyst Ratings Changes

REPL has been the topic of a number of analyst reports. Jefferies Financial Group upped their price objective on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. BMO Capital Markets lifted their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a report on Friday, November 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $17.29.

Replimune Group Price Performance

The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The company has a 50 day moving average of $12.44 and a 200-day moving average of $11.01. The firm has a market capitalization of $863.42 million, a P/E ratio of -4.14 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, sell-side analysts predict that Replimune Group, Inc. will post -2.91 EPS for the current year.

Insiders Place Their Bets

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 DIFC Ltd bought a new position in shares of Replimune Group in the second quarter worth about $57,000. Arizona State Retirement System acquired a new position in Replimune Group during the 2nd quarter worth approximately $108,000. Quest Partners LLC lifted its stake in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after purchasing an additional 3,150 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in Replimune Group in the third quarter valued at approximately $133,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Replimune Group by 82.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after buying an additional 5,926 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.